LifeSci Capital analyst Cory Jubinville, PhD maintained a Buy rating on Larimar Therapeutics today and set a price target of $33.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Cory Jubinville, PhD has given his Buy rating due to a combination of factors related to Larimar Therapeutics’ prospects. The survey conducted among physicians managing Friedreich’s ataxia (FA) patients indicates a cautiously positive sentiment towards Larimar’s nomlabofusp, with a notable percentage of physicians expressing satisfaction with its risk/benefit profile. This is despite some concerns about safety, such as instances of anaphylaxis, which do not seem to be major deterrents for prescribers or the FDA.
Furthermore, the potential for nomlabofusp to provide meaningful cardiac and neurological benefits is seen as promising, with many physicians optimistic about its efficacy. The survey results suggest that, if approved, a significant portion of eligible patients could be treated with nomlabofusp in combination with the existing therapy, Skyclarys. These factors, combined with the current market dynamics and physician sentiment, contribute to the Buy rating for Larimar Therapeutics’ stock.
In another report released yesterday, Guggenheim also reiterated a Buy rating on the stock with a $26.00 price target.